{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:30:08Z","timestamp":1793734208069,"version":"4.6.1"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has transformed neovascular age-related macular degeneration (nAMD) into a chronic, treatable condition. However, real-world outcomes remain limited by treatment burden, limited durability, variable response, and progression of atrophy or fibrosis, highlighting the need for strategies beyond VEGF-A suppression. This narrative review summarizes emerging therapeutic approaches aimed at addressing these unmet needs. Adjunctive pharmacologic targets, including angiopoietin\/Tie2 signaling, VEGF-C\/D, integrins, hypoxia-inducible pathways, and intracellular tyrosine kinase inhibition, are discussed. Gene-based therapies offering the potential for prolonged intraocular VEGF suppression are discussed, though challenges related to inflammation, irreversibility, and patient selection persist. Finally, surgical and regenerative strategies such as retinal pigment epithelium monolayer transplantation are reviewed as investigational options for highly selected patients. Collectively, these developments signal a shift toward individualized, multipronged nAMD management, with anti-VEGF therapy remaining foundational, while biomarkers, intraocular biochemical milieu, and patient adherence may guide future care.<\/jats:p>","DOI":"10.4103\/ijo.ijo_3274_25","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:01:08Z","timestamp":1777478468000},"page":"653-660","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Neovascular age-related macular degeneration management \u2013 Beyond anti-VEGF"],"prefix":"10.4103","volume":"74","author":[{"given":"Apoorva","family":"Ayachit","sequence":"first","affiliation":[{"name":"Department of Vitreoretina, M.M. Joshi Eye Institute, Hubballi, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailesh","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina, M.M. Joshi Eye Institute, Hubballi, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadma","family":"Eqbal","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina, M.M. Joshi Eye Institute, Hubballi, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giriraj","family":"Vibhute","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina, M.M. Joshi Eye Institute, Hubballi, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhat","family":"Fatima","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina, M.M. Joshi Eye Institute, Hubballi, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrinivas","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina, M.M. Joshi Eye Institute, Hubballi, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad","family":"Ayachit","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina, M.M. Joshi Eye Institute, Hubballi, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"R1-20261103","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"R2-20261103","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.gendis.2021.02.009","article-title":"Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy","volume":"9","author":"Deng","year":"2021","journal-title":"Genes Dis"},{"key":"R3-20261103","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R4-20261103","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"R5-20261103","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12886-020-01554-2","article-title":"Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - A systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems","volume":"20","author":"Finger","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"R6-20261103","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1001\/jamaophthalmol.2020.3989","article-title":"Lifetime outcomes of anti\u2013vascular endothelial growth factor treatment for neovascular age-related macular degeneration","volume":"138","author":"Finger","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R7-20261103","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ophtha.2009.09.002","article-title":"Vision-related function after ranibizumab treatment by better- or worse-seeing eye: Clinical trial results from MARINA and ANCHOR","volume":"117","author":"Bressler","year":"2010","journal-title":"Ophthalmology"},{"key":"R8-20261103","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"R9-20261103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OPTH.S1959","article-title":"Treatment of age-related macular degeneration: Focus on ranibizumab","volume":"2","author":"Spitzer","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"R10-20261103","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"R11-20261103","doi-asserted-by":"crossref","first-page":"e001328","DOI":"10.1136\/bmjophth-2023-001328","article-title":"Ten-year real-world outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration using pro re nata regimen","volume":"8","author":"Hujanen","year":"2023","journal-title":"BMJ Open Ophthalmol"},{"key":"R12-20261103","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/ceo.13949","article-title":"Neovascular age\u2010related macular degeneration: A review of findings from the real\u2010world Fight Retinal Blindness! registry","volume":"49","author":"Nguyen","year":"2021","journal-title":"Clin Exp Ophthalmol"},{"key":"R13-20261103","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13643-023-02261-x","article-title":"Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: A systematic review and meta-analysis","volume":"12","author":"Shahzad","year":"2023","journal-title":"Syst Rev"},{"key":"R14-20261103","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/eye.2015.48","article-title":"Defining response to anti-VEGF therapies in neovascular AMD","volume":"29","author":"Amoaku","year":"2015","journal-title":"Eye"},{"key":"R15-20261103","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1124\/jpet.122.001563","article-title":"Beyond VEGF: Targeting inflammation and other pathways for treatment of retinal disease","volume":"386","author":"Muniyandi","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"R16-20261103","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.4103\/ijo.IJO_1866_19","article-title":"Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema","volume":"68","author":"Kelkar","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R17-20261103","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.4103\/IJO.IJO_671_25","article-title":"Factors determining compliance with recommended intravitreal injections for retinal diseases among out-of-pocket, fully subsidized (non-paying), and insured patients: Real-world evidence from India","volume":"73","author":"Das","year":"2025","journal-title":"Indian J Ophthalmol"},{"key":"R18-20261103","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"R20-20261103","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1167\/iovs.07-0469","article-title":"Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761","volume":"48","author":"Fu","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R21-20261103","first-page":"936","article-title":"U.S. phase 1 study of intravitreal axitinib implant (OTX-TKI) for neovascular age-related macular degeneration","volume":"64","author":"Moshfeghi","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R22-20261103","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41419-025-08028-7","article-title":"HIF1 activity in photoreceptors drives type 3 neovascularization and retinal atrophy in a new mouse model of age-related macular degeneration","volume":"16","author":"Geiger","year":"2025","journal-title":"Cell Death Dis"},{"key":"R23-20261103","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41433-021-01842-1","article-title":"Review of gene therapies for age-related macular degeneration","volume":"36","author":"Khanani","year":"2022","journal-title":"Eye (Lond)"},{"key":"R24-20261103","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nbt.4114","article-title":"Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration","volume":"36","author":"da Cruz","year":"2018","journal-title":"Nat Biotechnol"},{"key":"R25-20261103","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI58832","article-title":"Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling","volume":"122","author":"Felcht","year":"2012","journal-title":"J Clin Invest"},{"key":"R26-20261103","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s13300-022-01326-9","article-title":"The role of angiopoietins in neovascular diabetes-related retinal diseases","volume":"13","author":"Collazos-Alem\u00e1n","year":"2022","journal-title":"Diabetes Ther"},{"key":"R27-20261103","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00417-024-06695-4","article-title":"Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases","volume":"263","author":"Chaudhary","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R28-20261103","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): Two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"R29-20261103","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: Two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in Year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"R30-20261103","first-page":"2187","article-title":"Visual and anatomic outcomes in nAMD patients with subretinal hemorrhage after treatment with faricimab in the TRUCKEE study","volume":"64","author":"Khan","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R31-20261103","first-page":"2218","article-title":"FARETINA-AMD- early treatment patterns and outcomes in patients with neovascular age-related macular degeneration initiating faricimab: An IRIS RegistryTM analysis","volume":"64","author":"Borkar","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R32-20261103","first-page":"4905","article-title":"Real-world treatment patterns and outcomes in the first 6 and 12 months of faricimab use among eyes with neovascular age-related macular degeneration (nAMD) in the UK: FARWIDE-nAMD","volume":"65","author":"Varma","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R33-20261103","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.2147\/OPTH.S527787","article-title":"Switching to faricimab for polypoidal choroidal vasculopathy with real-world outcomes in refractory cases - The FAR-PEARL study report 1","volume":"19","author":"Fong","year":"2025","journal-title":"Clin Ophthalmol"},{"key":"R34-20261103","first-page":"193","article-title":"Real-world data on faricimab switching in treatment-refractory neovascular age-related macular degeneration","volume":"14","author":"Ng","year":"2024","journal-title":"Life (Basel)"},{"key":"R35-20261103","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10792-025-03525-2","article-title":"Improved functional and morphological outcomes with faricimab in nAMD eyes with poor response to prior intravitreal anti-VEGF therapy","volume":"45","author":"Bleidi\u00dfel","year":"2025","journal-title":"Int Ophthalmol"},{"key":"R36-20261103","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41433-024-03373-x","article-title":"Exploring new horizons in neovascular age-related macular degeneration: Novel mechanisms of action and future therapeutic avenues","volume":"39","author":"Shirian","year":"2025","journal-title":"Eye"},{"key":"R37-20261103","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1167\/iovs.66.1.47","article-title":"The landscape of vascular endothelial growth factor inhibition in retinal diseases","volume":"66","author":"Lin","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R38-20261103","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41390-020-01177-9","article-title":"The role of integrins in inflammation and angiogenesis","volume":"89","author":"Mezu-Ndubuisi","year":"2021","journal-title":"Pediatr Res"},{"key":"R39-20261103","doi-asserted-by":"crossref","first-page":"9764","DOI":"10.1073\/pnas.93.18.9764","article-title":"Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases","volume":"93","author":"Friedlander","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R40-20261103","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/annonc\/mds281","article-title":"Phase Ib safety and pharmacokinetic study of volociximab, an anti-\u03b15\u03b21 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer","volume":"24","author":"Besse","year":"2013","journal-title":"Ann Oncol"},{"key":"R41-20261103","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/02713680701553052","article-title":"Modulation of hypoxia-induced neovascularization by JSM6427, an integrin alpha5beta1 inhibiting molecule","volume":"32","author":"Maier","year":"2007","journal-title":"Curr Eye Res"},{"key":"R42-20261103","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/13543784.2020.1795639","article-title":"Anti-integrin therapy for retinovascular diseases","volume":"29","author":"Bhatwadekar","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"R43-20261103","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1535-7163.MCT-06-0526","article-title":"Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis","volume":"6","author":"Fu","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"R44-20261103","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.3390\/ijms21082842","article-title":"Inhibition of hypoxia-inducible factor-1\u03b1 and vascular endothelial growth factor by Chrysin in a rat model of choroidal neovascularization","volume":"21","author":"Song","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R45-20261103","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.oret.2017.04.004","article-title":"Bevacizumab injection in patients with neovascular age-related macular degeneration increases angiogenic biomarkers","volume":"2","author":"Cabral","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R46-20261103","first-page":"673","article-title":"Assessment of treatment burden in wet age-related macular degeneration treated with EYP-1901 (vorolanib intravitreal insert) versus aflibercept: DAVIO 2 trial results","volume":"66","author":"Talcott","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R47-20261103","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/APO.0000000000000291","article-title":"Emerging therapies in neovascular age-related macular degeneration in 2020","volume":"9","author":"Samanta","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R48-20261103","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1208\/s12249-019-1474-0","article-title":"An in vitro assessment of thermo-reversible gel formulation containing sunitinib nanoparticles for neovascular age-related macular degeneration","volume":"20","author":"Bhatt","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"R49-20261103","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1038\/s41433-023-02610-z","article-title":"Tyrosine kinase inhibitors and their role in treating neovascular age-related macular degeneration and diabetic macular oedema","volume":"37","author":"Chandra","year":"2023","journal-title":"Eye (Lond)"},{"key":"R51-20261103","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/s41433-022-02262-5","article-title":"Retinal gene therapy in RPE-65 gene mediated inherited retinal dystrophy","volume":"37","author":"Jalil","year":"2023","journal-title":"Eye (Lond)"},{"key":"R52-20261103","doi-asserted-by":"crossref","first-page":"100915","DOI":"10.1016\/j.preteyeres.2020.100915","article-title":"Immune responses to retinal gene therapy using adeno-associated viral vectors \u2013 Implications for treatment success and safety","volume":"83","author":"Bucher","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"R53-20261103","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: A phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"key":"R54-20261103","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3390\/genes15060720","article-title":"Gene therapy for non-hereditary retinal disease: Age-related macular degeneration, diabetic retinopathy, and beyond","volume":"15","author":"Rowe","year":"2024","journal-title":"Genes (Basel)"},{"key":"R55-20261103","first-page":"1497","article-title":"Suprachoroidal delivery of RGX-314 gene therapy for neovascular AMD: The phase II AAVIATETM study","volume":"63","author":"Khanani","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R56-20261103","doi-asserted-by":"crossref","first-page":"102394","DOI":"10.1016\/j.eclinm.2023.102394","article-title":"Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): A prospective, two-year, multicentre phase 1 study","volume":"67","author":"Khanani","year":"2024","journal-title":"eClinicalMedicine"},{"key":"R57-20261103","first-page":"306","article-title":"Phase 1 study of intravitreal (IVT) gene therapy with ADVM-022 for neovascular AMD (OPTIC Trial): The role of neutralizing antibodies (NAbs)","volume":"63","author":"Kiss","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R58-20261103","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/IIO.0000000000000366","article-title":"Ocular inflammation and treatment emergent adverse events in retinal gene therapy","volume":"61","author":"Mehta","year":"2021","journal-title":"Int Ophthalmol Clin"},{"key":"R59-20261103","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3390\/diagnostics14101005","article-title":"The fate of RPE cells following hESC-RPE patch transplantation in haemorrhagic wet AMD: Pigmentation, extension of pigmentation, thickness of transplant, assessment for proliferation and visual function-A 5 year-follow up","volume":"14","author":"da Cruz","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"R60-20261103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.06.004","article-title":"Stem cell based therapies for age-related macular degeneration: The promises and the challenges","volume":"48","author":"Nazari","year":"2015","journal-title":"Prog Retin Eye Res"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3274_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:00:46Z","timestamp":1793732446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3274_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3274_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2025-12-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}